clinical trial · NCT05139121
Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
ContraceptionMR-100A-01
brief summary
Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles
started
Oct 26, 2021
primary completion
Jan 15, 2025
completion
Jan 15, 2025
last updated
Jan 28, 2025
detailed description
MR-100A-01 is a TDS of norelgestromin 4.86 mg/ethinyl estradiol 0.264 mg. This study will evaluate the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01.
official title
A Phase 3, Multicenter, Open-Label, Single Arm Study of MR-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol